List of Tekturna Hct drug patents

Tekturna Hct is owned by Noden Pharma.

Tekturna Hct contains Aliskiren Hemifumarate; Hydrochlorothiazide.

Tekturna Hct has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Tekturna Hct are:

  • US9023893

Tekturna Hct was authorised for market use on 18 January, 2008.

Tekturna Hct is available in tablet;oral dosage forms.

The generics of Tekturna Hct are possible to be released after 13 July, 2028.

TEKTURNA HCT's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9023893 NODEN PHARMA Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
Mar, 2022

(1 year, 17 days ago)

US8618172 NODEN PHARMA Galenical formulations of organic compounds
Jul, 2028

(5 years from now)

Drugs and Companies using ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE ingredient

Market Authorisation Date: 18 January, 2008

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TEKTURNA HCT before it's patent expiration?
More Information on Dosage

TEKTURNA HCT family patents

12

European Union

7

New Zealand

7

Korea, Republic of

7

Japan

6

United States

5

Spain

5

China

3

Portugal

3

Germany

3

Russia

3

Norway

3

Hong Kong

3

Canada

3

Slovenia

3

Israel

3

Poland

3

Australia

3

Denmark

2

United Kingdom

2

Brazil

2

Mexico

2

Austria

2

Peru

2

South Africa

2

Luxembourg

2

Hungary

2

Czech Republic

2

Ecuador

2

Netherlands

1

Singapore

1

Malaysia

1

Guatemala

1

Argentina

1

Morocco

1

Taiwan, Province of China

1

Tunisia

1

Slovakia

1

Cyprus

1

Chile

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in